Love the news in the report (hidden again) - key words "ramp materially" for Continuous Glucose Monitor in late FY21 and key words again "material agreement" for NanoDX once FDA approval.
Additionally within report I like the board comments "Based on its assessment of the cashflow projections over the ensuing 12 months from the date of this report, the Board is satisfied that sufficient funds are available for the Group to pay its debts as and when they fall due for at least the next 12 months from the date of this report"
